Undisclosed Asset
Rare Neurodegenerative Diseases
Pre-clinicalExpanded via partnership
Key Facts
Indication
Rare Neurodegenerative Diseases
Phase
Pre-clinical
Status
Expanded via partnership
Company
About Ipsen
Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.
View full company profile